Acute Corneal Hydrops in Keratoconus Patients with Graves’ Orbitopathy

Key Findings & Data:Two patients (Case 1: female, 54 years old; Case 2: male, 33 years old) with coexisting keratoconus and GO demonstrated typical findings of acute corneal hydrops (ACH) in 1 eye during the active stage of orbitopathy.

💡

Conclusion & Impact:Active GO can be a risk factor for ACH in keratoconus patients.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Özet

Presented are 2 cases of acute corneal hydrops in keratoconus with Graves’ orbitopathy (GO). Two patients (Case 1: female, 54 years old; Case 2: male, 33 years old) with coexisting keratoconus and GO demonstrated typical findings of acute corneal hydrops (ACH) in 1 eye during the active stage of orbitopathy. There was no history of trauma. The ACH healed with scarring after management with a therapeutic contact lens and medical treatment in each patient within 3 months and 5 months, respectively. The development of ACH in keratoconus patients has previously been reported to be associated with male gender, ethnicity, age, eye rubbing, trauma, rapidly progressive disease, atopy, and vernal conjunctivitis. GO involves ocular surface inflammation and fluctuation of intraocular pressure. Active GO can be a risk factor for ACH in keratoconus patients.

🔖

Cite This Article

DOĞAN, A. S., GÜRDAL, C., ÇELİKAY, O., BİLEN, R. B. A. (2021). Acute Corneal Hydrops in Keratoconus Patients with Graves’ Orbitopathy. BEYOGLU EYE JOURNAL, Cilt: 6 - Sayı: 4, 331–334. https://ajindex.com/articles/406554

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (10)

Fan Gaskin JC, Patel DV, McGhee CN. Acute corneal hydrops in keratoconus - new perspectives. Am J Ophthalmol 2014;157:921–8
Barsam A, Brennan N, Petrushkin H, Xing W, Quartilho A, Bunce C, et al. Case-control study of risk factors for acute corneal hydrops in keratoconus. Br J Ophthalmol 2017;101:499– 502
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al; European Group on Graves' Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of Graves' orbitopathy. Eur Thyroid J 2016;5:9–26
Kim JW, Ko J, Woo YJ, Bae HW, Yoon JS. prevalence of ocular hypertension and glaucoma as well as associated factors in Graves' Orbitopathy. J Glaucoma 2018;27:464–9
Mas Tur V, MacGregor C, Jayaswal R, O'Brart D, Maycock N. A review of keratoconus: Diagnosis, pathophysiology, and genetics. Surv Ophthalmol 2017;62:770–83
Thanos S, Oellers P, Meyer Zu Hörste M, Prokosch V, Schlatt S, Seitz B, et al. Role of thyroxine in the development of keratoconus. Cornea 2016;35:1338–46
McMonnies CW. The possible significance of the baropathic nature of keratectasia. Clin Exp Optom 2013;96:197–200 8. Taşçı YY, Taşlıpınar G, Eyidoğan D, Saraç Ö, Çağıl N. Five-year long-term results of standard collagen cross-linking therapy in patients with keratoconus. Turk J Ophthalmol 2020;50:200–5
Howard S, Raine J, Dattani M. Corneal rupture in a child with Down syndrome and hyperthyroidism. BMJ Case Rep 2009;2009:bcr08.2008.0842
Wisse RP, Kuiper JJ, Gans R, Imhof S, Radstake TR, Van der Lelij A. Cytokine expression in keratoconus and its corneal microenvironment: a systematic review. Ocul Surf 2015;13:272–83
Huang D, Xu N, Song Y, Wang P, Yang H. Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy. Graefes Arch Clin Exp Ophthalmol 2012;250:619–25.